DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Remibrutinib Dose A
Drug: Remibrutinib Dose B
Drug: Placebo 1
Drug: Placebo 2

First Posted Date: 2025-02-21

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 555

Registration Number: NCT06840392

Locations: 🇲🇾
Novartis Investigative Site, Wilayah Persekutuan, Malaysia
🇺🇸
Ctr Dermatology and Plastic Surgery, Scottsdale, Arizona, United States
🇺🇸
USC Keck School of Medicine, Los Angeles, California, United States

and more 23 locations

Ilaris NIS in Korea

Not yet recruiting

Conditions: Hereditary Periodic Fever Syndromes
Colchicine Resistance Familial Mediterranean Fever (crFMF)
Cryopyrin-associated Periodic Syndromes (CAPS)
TNF Receptor Associated Periodic Syndrome (TRAPS)
Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)
Systemic Juvenile Idiopathic Arthritis (sJIA)

Interventions: Biological: Ilaris

First Posted Date: 2025-02-20

Last Posted Date: 2025-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT06838143

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

Recruiting

Conditions: Breast Neoplasms

Interventions: Drug: ribociclib + NSAI ± LHRH
Drug: abemaciclib + ET ± LHRH
Drug: ET mono ± LHRH

First Posted Date: 2025-02-17

Last Posted Date: 2025-05-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3250

Registration Number: NCT06830720

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Phase 4

Not yet recruiting

Conditions: Graft vs. Host Disease
Chronic Graft vs. Host Disease
Corticosteroid-refractory Chronic Graft vs. Host Disease

Interventions: Drug: Ruxolitinib

First Posted Date: 2025-02-13

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT06824103

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Phase 3

Not yet recruiting

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD)

Interventions: Drug: Pelacarsen
Drug: Inclisiran
Drug: Placebo

First Posted Date: 2025-02-07

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 340

Registration Number: NCT06813911

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Remibrutinib Dose A
Drug: Remibrutinib Dose B
Drug: Placebo 1
Drug: Placebo 2

First Posted Date: 2025-01-29

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 555

Registration Number: NCT06799000

Locations: 🇺🇸
Cheryl Effron MD Inc, Anaheim, California, United States
🇺🇸
Olive View UCLA Medical Center, Sylmar, California, United States
🇺🇸
University of MiamiHealth System, Miami, Florida, United States

and more 17 locations

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

Not yet recruiting

Conditions: HR+/HER2- Early Breast Cancer

Interventions: Drug: ribociclib

First Posted Date: 2025-01-28

Last Posted Date: 2025-01-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 177

Registration Number: NCT06797531

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Phase 2

Not yet recruiting

Conditions: Glomerulonephritis, IGA
Immunoglobulin A Nephropathy

Interventions: Drug: Iptacopan

First Posted Date: 2025-01-28

Last Posted Date: 2025-01-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT06797518

Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Not yet recruiting

Conditions: Hidradenitis Suppurativa (HS)

First Posted Date: 2025-01-21

Last Posted Date: 2025-01-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 77

Registration Number: NCT06785779

Long-term Follow up Local Registry Study of Kymriah in South Korea

Not yet recruiting

Conditions: B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

First Posted Date: 2025-01-21

Last Posted Date: 2025-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT06785818

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy